No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides-a cross-sectional analysis with dose-response analyses.
Andriko PalmowskiMitsuteru AkahoshiBurkhard MucheZhivana BoyadzhievaSandra HermannChikashi C TeraoEdgar WiebeFrank ButtgereitPublished in: Rheumatology international (2023)
In the Rh-GIOP cohort, MTX is used in about a quarter of patients with PMR or vasculitis. It is not associated with BMD levels.